COMPANY NEWS

April 23, 2022

University of Camerino Signs Strategic Partnership with CureLab Veterinary to Revolutionize Cancer Treatment for Companion Animals

The university is also renewing its agreement with CureLab Oncology to support its phase II clinical trials

May 6, 2022

CureLab Veterinary Secures Patent Protection for P62 Plasmid Therapeutic in South Korea

Patent registration in South Korea enables CureLab Veterinary to pursue a market with high commercial potential

May 12, 2022

CureLab Veterinary’s DNA Plasmid, Elenavet, Designated a Biologic Veterinary Product by the European Medicines Agency

CureLab Veterinary plans to obtain regulatory approval in Europe, a market with significant revenue potential

September 14, 2022

CureLab Research Results With Cats Published in Animals Journal

Results published by CureLab scientists with the University of Camerino support targeting mammary gland cancers in cats via p62 plasmid